Annexin A2 in Tumors of the Gastrointestinal Tract, Liver, and Pancreas
Related Experiment Video
Updated: Jun 6, 2025
Author Spotlight: Revolutionizing Pancreatic Disease Understanding Through Advanced Intravital Imaging
Published on: October 6, 2023
Konstantinos Christofidis1,2, Alexandros Pergaris2, Rodanthi Fioretzaki3
1Cytopathology Laboratory, Laiko General Hospital of Athens, 11527 Athens, Greece.
Abstract:
Annexin A2 (ANXA2) is a protein that is involved in many physiological and pathological cellular processes. There is compelling evidence that its dysregulated expression, be it up- or downregulation, contributes to the oncogenesis of various neoplasms, including those of the digestive system. The present review summarizes the current knowledge on the role of ANXA2 in the main tumors of the digestive system. The clinical significance of ANXA2 is primordial, due to its potential use as a diagnostic and prognostic biomarker, and as a part of therapeutic protocols. Certain preclinical studies have shown that inhibiting ANXA2 or disrupting its interactions with key molecules can suppress tumor growth, invasion, and metastasis, as well as increase the cancer cells' sensitivity to treatment in various cancers. Further research is needed to fully elucidate the complex role of ANXA2 in the carcinogenesis of tumors of the digestive system, and to translate these findings into clinical applications for improved diagnosis, prognosis, and treatment.
Insights
Annexin A2 (ANXA2) protein dysregulation drives digestive system cancers. Inhibiting ANXA2 shows promise for cancer diagnosis, prognosis, and treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Annexin A2 (ANXA2) is implicated in cellular processes.
- ANXA2 dysregulation is linked to oncogenesis in various neoplasms.
- This review focuses on ANXA2's role in digestive system tumors.
Purpose of the Study:
- To summarize current knowledge on ANXA2 in digestive system tumors.
- To highlight ANXA2's clinical significance as a biomarker and therapeutic target.
- To review preclinical findings on ANXA2 inhibition in cancer.
Main Methods:
- Literature review of ANXA2's role in digestive system cancers.
- Analysis of preclinical studies on ANXA2 inhibition.
- Synthesis of current knowledge on ANXA2 in oncogenesis.
Main Results:
- ANXA2 dysregulation (upregulation or downregulation) contributes to digestive system cancer development.
- ANXA2 holds potential as a diagnostic and prognostic biomarker.
- Preclinical studies demonstrate ANXA2 inhibition suppresses tumor growth, invasion, and metastasis.
Conclusions:
- ANXA2 is a critical factor in digestive system carcinogenesis.
- ANXA2 inhibition may offer a novel therapeutic strategy.
- Further research is essential to translate ANXA2 findings into clinical applications for improved cancer care.
